12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

Shire neurology, autoimmune news

Shire recorded a $57.5 million charge in 4Q12 and said it reached an agreement in principle with the U.S. government to resolve civil litigation into Shire's U.S. sales and marketing practices relating to ADHD treatments Adderall XR extended-release dexamphetamine, Daytrana...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >